PREVYMIS

PREVYMIS is a medication prescribed to adults who have undergone an allogeneic hematopoietic stem cell transplant and are at a high risk of developing Cytomegalovirus (CMV) infection and disease. Its purpose is to prevent the occurrence of CMV infection and disease in these individuals.

Before making any changes to your medication regimen, it is important to inform your healthcare provider. PREVYMIS may cause various side effects such as nausea, diarrhea, vomiting, swelling in the arms and legs, cough, headache, tiredness, and abdominal pain. However, this is not an exhaustive list of potential side effects associated with PREVYMIS.

Prevymis is a medication prescribed to individuals who have undergone a stem cell or kidney transplant and are at a high risk of developing cytomegalovirus (CMV) infection and disease. Its purpose is to prevent the occurrence of CMV disease in these patients.

Prevymis is a medication that is prescribed to adults who are undergoing an allogeneic haematopoietic stem cell transplant in order to prevent illness caused by cytomegalovirus (CMV).

Letermovir, also known by its brand name Prevymis, is a medication used to treat cytomegalovirus (CMV) infections.

CMV can be treated by healthcare professionals using antiviral medications such as ganciclovir (GCV) or valganciclovir (VGC). These drugs can be administered through an IV infusion or taken orally as a pill. Typically, healthcare providers only treat CMV in individuals with weakened immune systems or newborns who exhibit symptoms of CMV.

Drug/Comparator Strength Average Daily Drug Cost ($)
Letermovir (Prevymis) 240 mg per vial $251.28
Letermovir (Prevymis) 480 mg per vial $493.78
Other CMV prophylaxis treatments
Ganciclovir (Cytovene) 500 mg per vial
Induction: $87.87
Maintenance: $43.93

Symptoms include hives, sleepiness, nausea, vomiting, diarrhea, uncontrollable shaking of a part of the body, headache, confusion, imbalance, extreme tiredness, swelling of arms or legs, and fever or other signs of infection.

Premature babies across the nation are in need of a unique blood type. Consider donating blood – if your blood is CMV negative, we will contact you! You have the potential to make a significant impact on the lives of babies like Braden. Discover how you can become a Hero for Babies.

You will be prescribed PREVYMIS to be taken once daily for approximately 1 hour at the same time each day. Your doctor will provide instructions on when to take your tablets. It is important not to break, crush, or chew the tablet.

People who are healthy and infected with CMV typically do not need medical treatment. However, individuals with weakened immune systems and babies showing signs of congenital CMV can receive medications to treat the infection.

Letermovir is an antiviral drug that specifically targets CMV (cytomegalovirus) and does not affect other herpesviruses. It works by inhibiting a specific component of the viral DNA terminase complex called subunit pUL56. This subunit is involved in the cleavage and packaging of viral DNA, and there is no equivalent target enzyme in the human body.

Intravenous ganciclovir is the preferred drug for treating CMV disease, although valganciclovir may be considered for nonsevere cases in certain situations. Ganciclovir is a nucleoside analogue that works by blocking DNA synthesis, similar to how acyclovir functions.

Merck’s Prevymis (letermovir) has received FDA approval for a new indication. It can now be used to prevent cytomegalovirus (CMV) disease in adult kidney transplant recipients who are at high risk.

Prevymis (letermovir) is an antiviral drug that has been approved by the FDA for the prevention of cytomegalovirus (CMV) infection in adults who have undergone a stem cell transplant and have tested positive for CMV.

You can request information about PREVYMIS from your pharmacist or healthcare provider that is specifically intended for healthcare professionals. The inactive ingredients in PREVYMIS tablets include colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and povidone 25.

Letermovir is a type of antiviral drug that is prescribed to adult transplant recipients who are at risk of developing cytomegalovirus (CMV) infection and disease as a preventive measure.

Merck’s PREVYMIS (letermovir) has received approval from the U.S. FDA for a new indication. It can now be used for the prevention of Cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients. This update was announced on Merck.com.

Prevymis is a medication prescribed to individuals who have undergone a stem cell or kidney transplant and are at a high risk of developing cytomegalovirus (CMV) infection and disease. Its purpose is to prevent the occurrence of CMV disease in these patients.

Letermovir belongs to a group of drugs known as antivirals, which function by inhibiting the replication of CMV, thereby impeding its growth.

Symptoms include a high temperature, muscle aches, fatigue, a skin rash, nausea, a sore throat, and swollen glands.

Letermovir, an antiviral agent, was first approved in 2017 for the purpose of preventing CMV infection and disease in adult patients who have undergone an allogeneic hematopoietic stem cell transplant and are CMV-seropositive.

Date: November 9, 2017
Article: FDA Approves Prevymis (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients

The price for a 14-tablet supply of Prevymis oral tablet 240 mg is approximately $3,678, but may vary depending on the pharmacy.

Prevymis (letermovir) is only available as a brand-name medication and should be taken once daily. It is important to note that Prevymis also has interactions with several other medications.

FDA has granted approval for Letermovir (Prevymis) to be used in adult kidney transplant patients as a preventive measure against CMV.

In the standard duration group, the median duration of letermovir prophylaxis was 78 days, while in the extended duration group, it was 132 days. The standard duration group had a higher percentage of CMV reactivations (28%) compared to the extended duration group (19%).

Given the significant myelosuppressive or renal toxicities associated with current standard of care CMV treatments, letermovir could potentially serve as a safe and effective alternative agent for CMV treatment, especially considering its favorable safety profile when used prophylactically.

Prevymis, marketed by Merck as Letermovir, received FDA approval in 2017 for the prevention of CMV infection and disease in adult CMV-seropositive patients undergoing allogeneic hematopoietic stem cell transplant (HSCT).

Prevymis (letermovir) is a medication that inhibits the CMV DNA terminase complex. It is used for the prevention of cytomegalovirus (CMV) infection and disease in adults who have received an allogeneic hematopoietic stem cell transplant (HSCT) and are CMV-seropositive.

The price of ganciclovir intravenous powder for injection 500 mg is approximately $707 for a pack of 10 powder for injection, varying depending on the pharmacy you choose.